Schlaepfer et al. revealed that treatment with the irreversible CPT1 inhibitor etomoxir in nude mice contributed to decreased prostate tumor xenograft growth over 21 days, highlighting the therapeutic potential of impairing lipid catabolism to decrease prostate cancer tumor growth [38]. Here, CPT1A is linked to prostate neoplasm.